Pro- and anti-angiogenic VEGF mRNAs in autoimmune thyroid diseases

References

• Viglietto, G., A. Romano, G. Manzo, et al. 1997. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene. 15: 2687–2698
   PubMed Web of Science ®Google Scholar
• Bahn, R. S., H. B. Burch, D. S. Cooper, et al. 2011. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 17: 456–520
   PubMed Web of Science ®Google Scholar
• Ganesh, B. B., P. Bhattacharya, A. Gopisetty, et al. 2011. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J. Interferon Cytokine Res. 31: 721–731
   PubMed Web of Science ®Google Scholar
• Vanderpump, M. P. J. 2011. The epidemiology of thyroid disease. Br Med Bull. 99: 39–51
   PubMed Web of Science ®Google Scholar
• Ramsden, J. D. 2000. Angiogenesis in the thyroid gland. J. Endocrinol. 166: 475–480
   PubMed Web of Science ®Google Scholar
• Mackay, I. R., and N. R. Rose. 2013. The Autoimmune Diseases. Academic Press, San Diego, CA
   Google Scholar
• Braverman, L. E., and D. Cooper. 2012. Werner & Ingbar's. The Thyroid. Lippincott Williams & Wilkins, Philadelphia, PA
   Google Scholar
• Iitaka, M., S. Miura, K. Yamanaka, et al. 1998. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves’ disease and Hashimoto’s thyroiditis. J. Clin. Endocrinol. Metab. 83: 3908–3912
   PubMed Web of Science ®Google Scholar
• Marazuela, M., F. Sánchez-Madrid, A. Acevedo, et al. 1995. Expression of vascular adhesion molecules on human endothelia in autoimmune thyroid disorders. Clin. Exp. Immunol. 102: 328–334
   PubMed Web of Science ®Google Scholar
• Phenekos, C., A. Vryonidou, A. D. Gritzapis, et al. 2004. Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto’s thyroiditis (Th1) and Graves’ disease (Th2). Neuroimmunomodulation. 11: 209–213
   PubMed Web of Science ®Google Scholar
• Tunbridge, W. M., D. C. Evered, R. Hall, et al. 1977. The spectrum of thyroid disease in a community: the Whickham survey. Clin. Endocrinol (Oxf). 7: 481–493
   PubMed Web of Science ®Google Scholar
• Weetman, A. P., and A. M. McGregor. 1994. Autoimmune thyroid disease: further developments in our understanding. Endocrine Rev. 15: 788–830
   PubMed Web of Science ®Google Scholar
• Szekanecz, Z., and A. E. Koch. 2007. Mechanisms of disease: angiogenesis in inflammatory diseases. Nat. Clin. Pract. Rheumatol. 3: 635–643
   PubMedGoogle Scholar
• Vural, P., S. Degirmencioglu, S. Erden, et al. 2009. The relationship between transforming growth factor-beta1, vascular endothelial growth factor, nitric oxide and Hashimoto's thyroiditis. Int. Immunopharmacol. 9: 212–215
   PubMed Web of Science ®Google Scholar
• Aust, G., K. Krohn, N. G. Morgenthaler, et al. 2006. Graves' disease and Hashimoto’s thyroiditis in monozygotic twins: case study as well as transcriptomic and immunohistological analysis of thyroid tissues. Eur. J. Endocrinol. 154: 13–20
   PubMed Web of Science ®Google Scholar
• Ferrara, N. 2009. VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine Netw. 20: 158–163
   PubMed Web of Science ®Google Scholar
• Dvorak, H. F., M. Detmar, K. P. Claffey, et al. 1995. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int. Arch. Allergy Immunol. 107: 233–235
   PubMed Web of Science ®Google Scholar
• Ancelin, M., S. Chollet-Martin, M. A. Hervé, et al. 2004. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab. Invest. 84: 502–512
   PubMed Web of Science ®Google Scholar
• Carvalho, J. F., M. Blank, Y. Shoenfeld. 2007. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J. Clin. Immunol. 27: 246–256
   PubMed Web of Science ®Google Scholar
• Hervé, M. A., H. Buteau-Lozano, R. Vassy, et al. 2008. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am. J. Pathol. 172: 167–178
   PubMed Web of Science ®Google Scholar
• Harper, S. J., and D. O. Bates. 2008. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat. Rev. Cancer. 8: 880–887
   PubMed Web of Science ®Google Scholar
• Catena, R., L. Larzabal, M. Larrayoz, et al. 2010. VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A. Mol. Cancer. 9: 320
   PubMed Web of Science ®Google Scholar
• Houck, K. A., D. W. Leung, A. M. Rowland, et al. 1992. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267: 26031–26037
   PubMed Web of Science ®Google Scholar
• Neufeld, G., T. Cohen, S. Gengrinovitch, et al. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13: 9–22
   PubMed Web of Science ®Google Scholar
• Bates, D. O., and S. J. Harper. 2002. Regulation of vascular permeability by vascular endothelial growth factors. Vasc. Pharmacol. 39: 225–237
   PubMed Web of Science ®Google Scholar
• Nowak, D. G., E. M. Amin, E. S. Rennel, et al. 2010. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. J. Biol. Chem. 285: 5532–5540
   PubMed Web of Science ®Google Scholar
• Fukumura, D., R. Xavier, T. Sugiura, et al. 1998. Tumor induction of VEGF promoter activity in stromal cells. Cell. 94: 715–725
   PubMed Web of Science ®Google Scholar
• Klein, M., E. Picard, J. M. Vignaud, et al. 1999. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J. Endocrinol. 161: 41–49
   PubMed Web of Science ®Google Scholar
• Ajjan, R. A., P. F. Watson, R. S. McIntosh, et al. 1996. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clin. Exp. Immunol. 105: 523–528
   PubMed Web of Science ®Google Scholar
• Viglietto, G., D. Maglione, M. Rambaldi, et al. 1995. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene. 11: 1569–1579
   PubMed Web of Science ®Google Scholar
• Wang, J. F., V. Milosveski, C. Schramek, et al. 1998. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J. Endocrinol. 157: 5–12
   PubMed Web of Science ®Google Scholar
• Garber, J. R., R. H. Cobin, H. Gharib, et al. 2012. American Association Of Clinical Endocrinologists And American Thyroid Association Taskforce On Hypothyroidism In Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 22: 1200–1235
   PubMed Web of Science ®Google Scholar
• Fitzgerald, S. P., J. V. Lamont, R. I. McConnell, et al. 2005. Development of a high-throughput automated analyzer using biochip array technology. Clin. Chem. 51: 1165–1176
   PubMed Web of Science ®Google Scholar
• Figueroa-Vega, N., P. Sanz-Cameno, R. Moreno-Otero, et al. 2009. Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J. Clin. Endocrinol. Metab. 94: 1145–1153
   PubMed Web of Science ®Google Scholar
• Barleon, B., S. Sozzani, D. Zhou, et al. 1996. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87: 3336–3343
   PubMed Web of Science ®Google Scholar
• Goebel, S., M. Huang, W. C. Davis, et al. 2006. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 290: 648–654
   PubMed Web of Science ®Google Scholar
• Mary, K. L., A. M. Shaker, B. D. Faith, et al. 2010. Thyroid hormone and angiogenesis. Vasc. Pharmacol. 52: 142–145
   PubMed Web of Science ®Google Scholar
• Zhao, X., G. Wang, J. You. 2013. Measurement and correlation analysis of plasma VEGF level in the patients of hyperthyroidism. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 30: 365–367
   PubMedGoogle Scholar
• Cooper, D. S. 2005. Antithyroid drugs. N. Engl. J. Med. 352: 905–917
   PubMed Web of Science ®Google Scholar
• Azimi Nezhad, M., M. G. Stathopoulou, A. Bonnefond, et al. 2013. Associations of vascular endothelial growth factor (VEGF) with adhesion and inflammation molecules in a healthy population. Cytokine. 61: 602–607
   PubMed Web of Science ®Google Scholar
• Schmid, C., M. Brändle, C. Zwimpfer, et al. 2004. Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor. Clin. Chem. 50: 228–231
   PubMed Web of Science ®Google Scholar